雲頂新耀－Ｂ (1952.HK)

23.500 -0.300 (-1.26%) 收市：04:08PM HKT

雲頂新耀－Ｂ

CITIC Pacific Plaza
16th Floor 1168 West Nanjing Road Jing’an District
Shanghai 200041
China

https://www.everestmedicines.com

版塊: Healthcare
行業: Biotechnology
全職員工: 432

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Wei Fu	Executive Chairman	無	無	1983
Mr. Yongqing Luo	CEO & Executive Director	11.89M	無	1970
Mr. Ian Ying Woo	CFO, President & Executive Director	12.28M	無	1973
Dr. Jason M. Brown Ph.D.	Chief Business Officer	無	無	1973
Dr. Wei Yang Ph.D.	Chief Scientific Officer	無	無	1970
Mr. Rico Liang	Chief Product Officer	無	無	1969
Ms. Sandra Zeng	Chief Medical Officer	無	無	無
Ms. Yee Wa Lau	Joint Company Secretary	無	無	1974
Ms. Leah Liu	Joint Company Secretary & VP of Corporate Affairs	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Everest Medicines Limited, a biopharmaceutical company, engages in discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; and Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator which is in phase 3 clinical trial for to treat moderate-to-severe active ulcerative colitis. The company also provides Zetomipzomib, a immunoproteasome inhibitor that is in phase 2b clinical trial, for a range of immune mediated disorders, including lupus nephritis; EVER001, a covalent reversible Bruton's tyrosine kinase (BTK) inhibitor which is in the phase 1b clinical trial for the treatment of renal diseases; and mRNA platform therapeutic vaccines for cancer and autoimmune diseases. Further, it offers EVER206, a polymyxin derivative designed to treat f MDR gram negative bacterial infections reduce toxicity and nephrotoxicity which is in phase 1 of clinical trial. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.

公司管治

截至 無 止，雲頂新耀－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。